New scan may help surgeons spot hidden prostate cancer during operation
NCT ID NCT06298838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests a new high-resolution PET-CT scan done during prostate cancer surgery to see if it can better detect cancer cells left behind or spread to lymph nodes. Ten men with high-risk prostate cancer will receive a special tracer injection before surgery, then get scanned while on the operating table. The goal is to see if this approach can guide surgeons more accurately than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients affected by Prostate cancer (PCa) with a risk of lymph node invasion (LNI) higher than 5% and candidates for a robot-assisted radical prostatectomy (RARP) with an extended pelvic lymph node dissection (ePLND) according to the European Association of Urology (EAU) guidelines.
- Ages
-
18 to 80 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male patient, 18 years of age or older. 2. Patient is confirmed with high risk prostate cancer. 3. Patient is indicated to undergo radical prostatectomy and ePLND. 4. Patient is estimated compliant for study participation by the investigator. 5. Patient has freely given his/her informed consent to participate in this study. Exclusion Criteria: 1. Patient has general or local contra-indications for radical prostatectomy. 2. Patient has active viral or fungal infection. 3. Patient previously received radiotherapy of the prostate. 4. Patient participated in other clinical studies with radiation exposure of more than 1 mSv in the past year.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?